Biovest International Inc.(fka BVTIQ)

[mlkrborn]

Biovest announces that FDA Grants Orphan Drug Status for personalized cancer vaccine for the treatment of Waldenstrom's Macroglobulinemia (BVTI) 0.44 +0.06 : Co announced that the FDA has granted Orphan Drug Designation to BiovaxID for the treatment of Waldenstrom's macroglobulinemia, a rare subtype of B-cell non-Hodgkin's lymphoma. This milestone advances Biovest's plans to develop and commercialize BiovaxID as an autologous active immunotherapy (personalized cancer vaccine) for the treatment of multiple subtypes of B-cell non-Hodgkin's lymphoma including follicular lymphoma and mantle cell lymphoma... Biovest is majority-owned subsidiary of Accentia Biopharmaceuticals (ABPI).